Myeloproliferative Neoplasms

MPN Genomic Calculator Performs Well in Real-Life Cohort of Patients With Essential Thrombocythemia

By

Susan Moench, PhD, PA-C

Publish Date July 29, 2020

The MPN Genomic Calculator uses clinical, laboratory, and genomic characteristics of patients with MPN to estimate their clinical outcomes.

Cutaneous AEs Are Common in Patients With MPNs Treated With Hydroxyurea

By

Susan Moench, PhD, PA-C

Publish Date July 27, 2020

Previously conducted retrospective studies may have underestimated the incidence of hydroxyurea-related skin toxicity in patients with MPNs.

Infection Risk for Patients With Myeloproliferative Neoplasms

By

Vicki Moore, PhD

Publish Date July 9, 2020

Matched cohort study showed risk greatest for those with primary myelofibrosis, but still high for those with polycythemia vera and essential thrombocythemia.

High-Risk Mutations May Underlie Worse Outcomes in Men With MPN, Study Suggests

By

Susan Moench, PhD, PA-C

Publish Date July 1, 2020

This study showed that MPN is more aggressive in men vs women and explored whether sex differences in the genomic landscape of MPN could explain this difference.

Evaluation of Real-World Experience With Long-Term Use of Anagrelide in the Setting of Essential Thrombocythemia

By

Susan Moench, PhD, PA-C

Publish Date June 10, 2020

Anagrelide, a platelet-lowering agent with US FDA approval and EMA licensing for the treatment of patients with ET, is associated with prolonged response to initial therapy.